MPR First Report

Adding carboplatin to standard neoadjuvant chemotherapy improved outcomes in younger patients with triple-negative breast cancer.

Combination cemiplimab, REGN3767, and chemotherapy appears effective in triple-negative breast cancer and HR+, HER2- breast cancer.

Patients with germline pathogenic variants in BRCA1, BRCA2, and CHEK2 have an increased risk of contralateral breast cancer.

The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.

Ribociclib plus endocrine therapy prolongs progression-free survival when compared with chemotherapy in HR+/ HER2− advanced breast cancer.

A retrospective study revealed characteristics of patients with metastatic breast cancer who are not likely to receive first-line systemic therapy.

Interrupting endocrine therapy so patients with breast cancer can attempt pregnancy does not appear to impact short-term disease outcomes.

Continuing CDK4/6 inhibitor therapy and switching ET after disease progression does not improve progression-free survival vs switching ET alone in HR+, HER2- metastatic breast cancer.

Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.

Neoadjuvant trastuzumab deruxtecan appears active in patients with HER2-low, hormone receptor-positive, early breast cancer.